Skip to main content
Delfa

← All trials/NCT02127996

GOLD-PCI

UnknownPhase 2

GLP-1 Loading During Elective Percutaneous Coronary Intervention

A Study to Investigate the Protective Effects of Glucagon-like Peptide-1 (GLP-1) in Patients Undergoing Elective Angioplasty and Stenting (GOLD-PCI)

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

-

Actual enrollment

193

Study population

Cardiovascular disease, Heart failure

Eligibility highlights

-

Primary endpoint

•Plasma Troponin I level

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02127996
Org study IDP01799

Timeline

Milestones

Study first posted2014-05-01estimated
Primary completion2017-03-31actual
Last update posted2018-06-06actual
Study start2015-03 (month precision)
Study completion2021-07estimated (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Cardiovascular diseaseHeart failure

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Undergoing elective PCI
•Age over 18
•Able to give informed consent

Exclusion criteria

•Severe co-morbidity (expected life expectancy < 6 months)
•Nicorandil, glibenclamide, sitagliptin, vildagliptin, saxagliptin, linagliptin, liraglutide, exenatide and insulin use
•Women of child bearing age
•Breast-feeding women
•Myocardial infarction within the previous 3 months
•Baseline elevation of Troponin I before PCI
•Chronic Renal Impairment (serum creatinine > 160 μmol/l)

Endpoints (9)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
7
Cardiovascular outcomes
1
Safety / tolerability / PK
1

Cardiovascular outcomes

1 endpoint
Secondary/protocol endpoint

Major Adverse Cardiovascular or Cerebrovascular Event (MACCE) Rates

Time frame:From date of randomisation until the date of first event assessed up to 6 months

descriptive

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Electrocardiographic (ECG) Changes during procedure

Time frame:Assessed during procedure

descriptive

Other (unclassified)

7 endpoints
Primary/protocol endpoint/low confidence

Plasma Troponin I level

Time frame:6 Hours following angioplasty or stenting

concentration, descriptive

Secondary/protocol endpoint/low confidence

Plasma Creatine Kinase - Myocardial Bound (CKMB) level

Time frame:6 hours

concentration, descriptive

Secondary/protocol endpoint/low confidence

Myocardial Flow Grade after Angioplasty or Stenting

Time frame:Measured during procedure

descriptive

Secondary/protocol endpoint/low confidence

MACCE Rates

Time frame:From date of randomisation until the date of first event assessed up to 12 months

descriptive

Secondary/protocol endpoint/low confidence

MACCE Rates

Time frame:From date of randomisation until the date of first event assessed up to 60 months

descriptive

Secondary/protocol endpoint/low confidence

Ischaemic symptoms during balloon occlusion

Time frame:Assessed during procedure

descriptive

Secondary/protocol endpoint/low confidence

Myocardial Blush Grade following angioplasty or stenting

Time frame:Measured during procedure

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.